Bildkälla: Stockfoto

InDex Pharmaceuticals: Discontinues development of cobitolimod - Redeye

Redeye provides its comments on yesterday's news that InDex Pharmaceuticals discontinues the development of cobitolimod and will not proceed development of any of its other compounds.

Redeye provides its comments on yesterday's news that InDex Pharmaceuticals discontinues the development of cobitolimod and will not proceed development of any of its other compounds.
Börsvärldens nyhetsbrev
ANNONSER